Department of Physiology & Electrophysiology Research Centre, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Basic Clin Pharmacol Toxicol. 2012 Jun;110(6):487-93. doi: 10.1111/j.1742-7843.2011.00848.x. Epub 2012 Jan 20.
In this study, we investigated the therapeutic effects of simvastatin administered in combination with bone marrow stromal cells (BMSCs) following experimentally induced embolic stroke in rats. Effects on infarct volume, brain oedema and neurological deficits were examined. Focal ischaemic brain injury was induced by emblazing a preformed clot into the middle cerebral artery in rats. Animals were administered simvastatin (40 mg/kg) at 1 hr after stroke, or BMSCs (3 × 10(6)) at 24 hr after stroke or a combination of these two treatments. Rats receiving a dose of simvastatin in combination with BMSC administration demonstrated a significant reduction in neurological deficits, a significant reduction in infarct volume and a significant decrease in brain oedema. Our data show that combining simvastatin administration with BMSCs has an additive effect on improving functional outcome in this thromboembolic stroke model.
在这项研究中,我们研究了辛伐他汀联合骨髓基质细胞(BMSCs)治疗实验性大鼠栓塞性卒中的疗效。检测了对梗死体积、脑水肿和神经功能缺损的影响。通过将预先形成的血栓嵌入大鼠大脑中动脉来诱导局灶性缺血性脑损伤。在卒中后 1 小时给予辛伐他汀(40mg/kg),或在卒中后 24 小时给予 BMSCs(3×10(6)),或联合使用这两种治疗方法。给予辛伐他汀联合 BMSC 给药剂量的大鼠表现出神经功能缺损显著减少,梗死体积显著减小,脑水肿显著减轻。我们的数据表明,辛伐他汀联合 BMSCs 给药在改善这种血栓栓塞性卒中模型的功能结果方面具有相加作用。